Your browser doesn't support javascript.
loading
Investigating the mechanism of cornel iridoid glycosides on type 2 diabetes mellitus using serum and urine metabolites in rats.
Hou, Yadi; Huang, Yanmei; Shang, Zihui; Ma, Shichao; Cui, Tianyi; Chen, Ali; Cui, Yongxia; Chen, Suiqing.
Afiliação
  • Hou Y; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address: Hyd991130@163.com.
  • Huang Y; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address: ymhuang2012@163.com.
  • Shang Z; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address: shangzihui@126.com.
  • Ma S; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address: 1299899166@qq.com.
  • Cui T; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address: 2818606302@qq.com.
  • Chen A; School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou, 510006, China. Electronic address: chenali2004@163.com.
  • Cui Y; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address: tianshicui@hactcm.edu.cn.
  • Chen S; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China; Henan Provincial Key Laboratory of Chinese Medicine Resources and Chinese Medicine Chemistry, Henan University of Chinese Medicine, Zhengzhou, 450046, China; Henan University of Chinese Medicine, Collaborative Innov
J Ethnopharmacol ; 328: 118065, 2024 Jun 28.
Article em En | MEDLINE | ID: mdl-38508432
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE Cornel iridoid glycosides (CIG) are extracted from Corni fructus, a herbal medicine used in traditional Chinese medicine to treat diabetes. However, the antidiabetic effects of CIG and the underlying metabolic mechanisms require further exploration. AIM OF THE STUDY This study aimed to assess the antidiabetic effects and metabolic mechanism of CIG by performing metabolomic analyses of serum and urine samples of rats. MATERIALS AND

METHODS:

A rat model of type 2 diabetes mellitus (T2DM) was established by administering a low dose of streptozotocin (30 mg/kg) intraperitoneally after 4 weeks of feeding a high-fat diet. The model was evaluated based on several parameters, including fasting blood glucose (FBG), random blood glucose (RBG), urine volume, liver index, body weight, histopathological sections, and serum biochemical parameters. Subsequently, serum and urine metabolomics were analyzed using ultra-high-pressure liquid chromatography coupled with linear ion trap-Orbitrap tandem mass spectrometry (UHPLC-LTQ-Orbitrap-MS). Data were analyzed using unsupervised principal component analysis (PCA) and supervised orthogonal partial least squares discriminant analysis (OPLS-DA). Differential metabolites were examined by the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways to explore the underlying mechanisms.

RESULTS:

After 4 weeks of treatment with different doses of CIG, varying degrees of antidiabetic effects were observed, along with reduced liver and pancreatic injury, and improved oxidative stress levels. Compared with the T2DM group, 19 and 23 differential metabolites were detected in the serum and urine of the CIG treatment group, respectively. The key metabolites involved in pathway regulation include taurine, chenodeoxycholic acid, glycocholic acid, and L-tyrosine in the serum and glycine, hippuric acid, phenylacetylglycine, citric acid, and D-glucuronic acid in the urine, which are related to lipid, amino acid, energy, and carbohydrate metabolism.

CONCLUSIONS:

This study confirmed the antidiabetic effects of CIG and revealed that CIG effectively controlled metabolic disorders in T2DM rats. This seems to be meaningful for the clinical application of CIG, and can benefit further studies on CIG mechanism.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Diabetes Mellitus Tipo 2 Limite: Animals Idioma: En Revista: J Ethnopharmacol Ano de publicação: 2024 Tipo de documento: Article País de publicação: Irlanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Diabetes Mellitus Tipo 2 Limite: Animals Idioma: En Revista: J Ethnopharmacol Ano de publicação: 2024 Tipo de documento: Article País de publicação: Irlanda